Seven moderately hypercholesterolemic subjects were studied before and after 10 weeks of simvastatin therapy (20 mg/day). Therapy reduced low density lipoprotein (LDL) cholesterol by 39% (p<0.001), whereas high density lipoprotein and very low density lipoprotein (VLDL) cholesterol were unchanged. Apolipoprotein (apo) B-containing lipoproteins were divided into VLDL, (S, 60-400), VLDL 2 (S r 20-60), intermediate density lipoprotein , and LDL (S r 0-12), and metabolic changes were sought in dual-tracer VLDL] and VLDL 2 turnover studies. VLDL, apoB pool size was unaltered by therapy, as were its rates of synthesis, catabolism, and delipidation to VLDL 2 . Similarly, the VLDL 2 apoB pool size was unchanged, but its metabolic fate was altered. The IDL pool size fell significantly (27%, p< 0.01) due entirely to an increased fractional catabolism of the lipoprotein. In our subjects, the circulating mass of LDL apoB decreased (49%, p< 0.01) primarily due to a reduction in its synthesis. Before therapy, 30% of the apoB entering the delipidation cascade in these hyperlipidemic subjects was converted to LDL. On therapy the input remained the same, but direct catabolism from VLDL 2 and IDL was increased (p<0.05), and as a result only 16% eventually appeared in LDL. These kinetic changes were associated with a fall in particle cholesteryl ester content throughout the delipidation cascade. We also observed a link between LDL kinetics and its subfraction distribution. Simvastatin influences the metabolism of LDL, IDL, and VLDL 2 but not VLDL,. {Arteriosclerosis and Thrombosis 1993;13:170-189) KEY and more recently from the Helsinki Heart Study 3 has confirmed the importance of lipid lowering as a means of preventing coronary heart disease (CHD). Since the completion of these studies, more powerful lipid-regulating agents have become available; the most potent of these in terms of low density lipoprotein cholesterol (LDL-C) lowering are the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors or "statins." This is an important class of lipid-lowering drugs whose remarkable efficacy has been documented in studies of several different groups of patients. 4 " 10 The precise mechanism of action of these compounds, however, has not been fully elucidated. At first it was thought that they affected only LDL via activation of hepatic apolipoprotein (apo) B/E receptors. However, further experience has suggested that they have substantial effects on very low density In general, all statins have weak but significant plasma triglyceride-lowering properties; in type III hyperlipoproteinemic subjects it has been shown that statins can, uniquely among lipid-lowering drugs, correct the compositional abnormality seen in VLDL. 9 Investigations of the kinetic changes underlying the LDL reduction on statin therapy have revealed an unsuspected heterogeneity of response. Many subjects, particularly those with familial hypercholesterolemia (FH), exhibit an increase in apoLDL clearance while on the drug, 13 whereas in others decreased production of the lipoprotein is the principal cause of reduced LDL concentration in the circulation. 11 This variable response to a drug with a simple, known mechanism of action suggests that inhibition of cholesterol synthesis in vivo has wideranging effects on apoB metabolism. Whether the statininduced changes are solely consequent on increased apoB/E receptor activity remains to be determined. Certainly in previous studies we have been able to demonstrate that the receptor has a role to play in the metabolism of apoB-containing lipoproteins throughout most of the S f 0-400 density range.
T he publication of the findings from the Lipid
Research Clinics Primary Prevention Trial 1 ' 2 and more recently from the Helsinki Heart Study 3 has confirmed the importance of lipid lowering as a means of preventing coronary heart disease (CHD). Since the completion of these studies, more powerful lipid-regulating agents have become available; the most potent of these in terms of low density lipoprotein cholesterol (LDL-C) lowering are the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors or "statins." This is an important class of lipid-lowering drugs whose remarkable efficacy has been documented in studies of several different groups of patients. 4 " 10 The precise mechanism of action of these compounds, however, has not been fully elucidated. At first it was thought that they affected only LDL via activation of hepatic apolipoprotein (apo) B/E receptors. However, further experience has suggested that they have substantial effects on very low density In general, all statins have weak but significant plasma triglyceride-lowering properties; in type III hyperlipoproteinemic subjects it has been shown that statins can, uniquely among lipid-lowering drugs, correct the compositional abnormality seen in VLDL. 9 Investigations of the kinetic changes underlying the LDL reduction on statin therapy have revealed an unsuspected heterogeneity of response. Many subjects, particularly those with familial hypercholesterolemia (FH), exhibit an increase in apoLDL clearance while on the drug, 13 whereas in others decreased production of the lipoprotein is the principal cause of reduced LDL concentration in the circulation. 11 This variable response to a drug with a simple, known mechanism of action suggests that inhibition of cholesterol synthesis in vivo has wideranging effects on apoB metabolism. Whether the statininduced changes are solely consequent on increased apoB/E receptor activity remains to be determined. Certainly in previous studies we have been able to demonstrate that the receptor has a role to play in the metabolism of apoB-containing lipoproteins throughout most of the S f 0-400 density range. 1415 Receptor deficiency in FH leads to accumulation of VLDL 2 , IDL, and LDL. 14 At the other extreme, upregulation of receptors in subjects with apoE^ homozygosity has a profound effect on all apoB-containing classes. Medical problems of subjects at start of study.
will most likely receive such therapy, i.e., patients with primary, moderate hypercholesterolemia. The dual VLDL, and VLDL 2 tracer turnover technique that we employed has been previously applied to the study of the VLDL delipidation cascade in FH, 14 hepatic lipase deficiency, 16 and subjects with different apoE phenotypes. 15 While a new method to determine LDL substructure has been used successfully to examine the LDL subfraction distribution in normal subjects and those with CHD 1718 and to look at the effects of other lipid-lowering drugs, 19 it was thought that application of these powerful techniques and correlation of kinetic parameters with VLDL and LDL structural information would yield new insight into lipoprotein physiology and the mechanism of action of the HMG CoA reductase inhibitor simvastatin. This, indeed, proved to be the case. Significant correlations were observed between LDL-9poB kinetic parameters and LDL substructure. The effects of the drug were isolated to specific pathways throughout the delipidation cascade that are believed to be receptor dependent.
Methods

Subjects
Seven study patients were selected from the lipid clinics at Glasgow Royal Infirmary and Hairmyres Hos- NS VLDL-C, very low density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; NS, not significant.
•Cholesterol, triglyceride, VLDL-C, LDL-C, and HDL*C figures are means of three measurements over the 13-day turnover period. pital, East Kilbride. All had an initial elevated total cholesterol level (>7.0 mmol/1) despite adherence to a standard lipid-lowering diet (European Atherosclerosis Society dietary recommendations, Reference 20) and a trigryceride level <4.0 mmol/1 but did not have FH. One subject's (S.H.) cholesterol level fell below 7.0 mmol/1, but because he had previously satisfied the inclusion criteria on three occasions, he was continued in the study. Patients were screened for cardiological, hematologic, hepatic, endocrine, renal, ophthalmologic, and metabolic disease by routine clinical and laboratory testing. Premenopausal women were excluded from the study. The characteristics of each patient are summarized in Table 1 . Five of the seven subjects studied were receiving prescribed medications for other clinical conditions, and these were continued unchanged throughout the course of the study. Of the drugs being taken, only hydrochlorthiazide in subject A.W. would be expected to have a modest effect on plasma lipids. The consistency of the lipid and metabolic changes in all subjects indicates that administration of these other drugs did not affect the outcome of the study.
Study Protocol
This was a single-blind study comprising three phases designed to examine the influence of simvastatin on the metabolism of apoB-containing particles. These phases were: 1) Preliminary screening period. During this 5-week period each patient was screened for cardiological, hematologic, hepatic, endocrine, renal, ophthalmologic, and metabolic disease by routine clinical and laboratory testing. 2) Placebo baseline period. For 4 weeks each patient received placebo, and in the final 2 weeks of this period a VLDL turnover study was performed on each patient to serve as a control. Baseline lipid, lipoprotein, and lipoprotein subfractions were measured as described below. 3) Active treatment period. Immediately after the baseline assessment of apolipoprotein metabolism, the patients were started on simvastatin therapy at an initial dose of 10 mg/day, rising to 20 mg/day after 4 weeks. The final dose of 20 mg is the usual daily dose of simvastatin used in the United Kingdom and is analogous to approximately 40 mg lovastatin. Patients remained on this dose for 10 weeks. During the final 2 weeks each patient underwent a second turnover investigation while on simvastatin therapy. In addition, lipid, lipoprotein, and lipoprotein subfraction analyses were repeated.
Lipid and Lipoprotein Analysis
The plasma lipid and lipoprotein levels (shown in Table 2 ) were measured on three occasions throughout the 13-day turnover period according to the Lipid Research Clinics Protocol. 21 The plasma HDL subfraction masses were determined by analytical ultracentrifugation, 22 and the plasma LDL subfraction profiles were determined by nonequilibrium density gradient centrifugation as described by Griffin et al. 18 In the latter procedure, fresh plasma was fractionated into three distinct LDL subfractions on a six-step, curvilinear salt gradient that was subjected to 24-hour centrifugation in a Beckman SW40 rotor (40,000 rpm, 23°C). After centrifugation, the LDL subfractions were eluted by upward displacement and detected by continuous monitoring of absorbance at 280 nm. This separation technique generated LDL subfraction profiles in which it was possible to resolve three subtractions that corresponded in size and density to those described by Krauss, 17 namely LDL-I, LDL-II, and LDL-III. The individual subfraction areas beneath the LDL profile were quantified using DATA LEADER software (Beckman). The integrated areas, after being adjusted by specific extinction coefficients calculated previously for LDL-I, -II, and -III, were expressed as fractions of total LDL mass by proportioning the lipid and protein mass of total LDL (density, 1.019-1.063 g/ml). This provided concentration values for each LDL subfraction in milligrams of lipoprotein per 100 ml of plasma. 18 
Lipoprotein Isolation and Labeling
The methods for preparation of the tracer VLDL subfractions VLDL, (S f 60-400) and VLDL 2 (S f 20-60) have been described in detail elsewhere. 23 Briefly, 250 ml fasting plasma was collected by plasmapheresis and from this, total VLDL (d< 1.006 g/ml, S f 20-400) was isolated by centrifugation for 22 hours at 39,000 rpm and 10°C in a Beckman Ti60 rotor. The supernatant VLDL was harvested and used for the preparation of the subfractions. The VLDL solution was adjusted to a density of 1,118 g/ml by the addition of solid sodium chloride (0.34 g per 2 ml solution) and layered in a Beckman SW40 rotor tube that had been precoated with polyvinyl alcohol to reduce internal surface tension and permit improved layering. A six-step gradient (d, 1.0988-1.0588 g/ml) was 24 and sterilized immediately before reinjection by filtration through a 0.45 -jun filter (Acrodisc, Gelman Sciences).
Turnover Protocol
On the third day after plasmapheresis, each subject was admitted at 8 AM after an overnight fast and the concentration of 1 mg/ml. To minimize chylomicron production, the subject remained fasting for the first 10 hours of the study but was allowed unlimited noncaloric fluids. Plasma was obtained from each of the blood samples by low-speed centrifugation at l,000g at 4°C. ylurea (TMU) at 37°C to each lipoprotein fraction. 26 The apoB pellet was delipidated by extraction with organic solvents (ethanol/diethyl ether, 3:1 vol/vol) overnight at -20°C. The protein pellet was reformed by further low-speed centrifugation and the solvent removed. The pellet was dried with a diethyl ether wash for 2 hours at -20°C, and after removal of the ether, the samples were placed uncapped in an incubator at 40°C for 10 minutes or until all solvent had evaporated. The isolated apoB was redissolved by adding 1.0 ml of 0.5 M NaOH, and the samples were left at 3TC until dissolution was complete. Specific activities were determined by radioactivity counting and protein assay 27 in each fraction. 
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ApoB concentrations in the apoB-containing lipoprotein classes were determined by replicate analyses of S f 0-400 lipoproteins collected at four times throughout the study. Correction for centrifugal losses was made by comparing the recovered VLDL,+VLDL 2 +IDL+LDL cholesterol to the "non-HDL" cholesterol in plasma. 14 Pool sizes for apoB in the four lipoprotein fractions were calculated from the product of plasma volume (taken as 4% of body weight) and the plasma concentration of apoB in each fraction. As a check, total plasma apoB was also measured by an automated immunoturbidimetric method using a commercially available kit (Orion Diagnostica, Espoo, Finland). The composition of each lipoprotein fraction was determined by assaying total and esterified cholesterol, triglycerides, phospholipids, and protein. 28 The concentrations of cholesterol, triglycerides, free cholesterol, and phospholipids in the lipoprotein fractions were determined by enzymatic, colorimetric assays using commercially available reagents (BCL, East Sussex, UK; catalog Nos.: cholesterol, 816302; triglyceride, 816370; free cholesterol, 310328; and phospholipid, 691844). Protein measurements were performed according to the method of Lowry et al. 27 In all studies it was essential to ensure that thyroidal uptake of radioiodide had been blocked by the oral administration of potassium iodate (170 mg twice daily). This regimen was commenced 3 days before injection of radiolabeled lipoproteins and was continued for the next 28 days. The turnover studies were conducted on an outpatient basis, and all subjects were instructed to adhere strictly to their established lipid-lowering diet and lifestyle. This was done to ensure free-living steadystate conditions for the investigation of lipoprotein metabolism.
Kinetic Analysis
The radioactivity associated with the apoB present in each lipoprotein fraction (VLDL,, VLDL 2 , IDL, and LDL) was calculated as the product of apoB specific activities and the individual pool sizes. These were then expressed as a percentage of total apoB radioactivity present in the subjects' plasma 10 minutes after injection, and the resulting values were used to construct decay curves. These were analyzed by the SAAM 30 multicompartmental modeling program 29 on a VAX system. The metabolic model that was used is shown in Figure 1 and is essentially that described elsewhere 1523 with the exception that two further subcompartments have been added in VLDL, to take into account the second, slower exponential that is seen in some individuals. The main features of the model are as follows: 1) apoB direct input may occur at the level of VLDL,, VLDL 2 , and LDL; 2) VLDL is delipidated in a stepwise manner following the concept of Berman et al 30 ; 3) slowly catabolized, remnant pools are present in VLDL 2 and IDL; and 4) two The fitting of the calculated values to observed values was accepted when the decay curves showed no systematic error and when the estimated pool sizes for VLDL!, VLDL 2 , and IDL were within 15% of the measured values.
The rate constants, fluxes, and apoB masses were compared in each subject before and after 10 weeks' simvastatin therapy by paired Student's t test.
Ethical Considerations
All subjects participating in the study gave informed, written consent. The study met with the requirements of the ethics committee of Glasgow Royal Infirmary.
Results
Simvastatin was well tolerated by all subjects participating in the study. Biochemical and hematologic monitoring revealed no clinically significant changes from baseline attributable to therapy. Ophthalmologic examination with a slit lamp failed to detect alteration in the lens of any subject. Treatment reduced plasma cholesterol (Table 2) by 29% (p<0.001). Triglycerides were not significantly affected, although there was a tendency (/>=0.091) for a decrease on therapy. The decrease in cholesterol was due to a 39% fall in LDL-C, whereas VLDL cholesterol (VLDL-C) and HDL cholesterol (HDL-C) were unchanged. Centrifugal analysis of the subfraction distribution in the LDL and HDL density intervals revealed that these had been perturbed by simvastatin treatment. HDL 2 was increased significantly by 62% (/7<0.01), whereas HDL 3 was unaffected. The change in HDL 2 concentration was correlated inversely with the fall in triglyceride levels for the group as a whole (r=0.70). Figure 2 shows the LDL subfraction profile obtained on density gradient fractionation of the subjects' plasma. The pattern exhibited considerable variation from subject to subject, but in most three distinct populations of particles could be distinguished both before and during therapy. The decrease in the major LDL-II species was the most obvious change in our subjects. Quantitative analysis revealed that its concentration fell by 39% (/?<0.02). LDL-I, the least dense fraction, was also reduced significantly by 31% (/?<0.02). In subjects in whom LDL-III was high (Figure 2, Table 3 ), it appeared to fall substantially, but a number of subjects in whom it was a minor fraction recorded no change. Thus, despite a 30% reduction in its mean value (Table 3) , the overall effect was not statistically significant. Compositional analysis of the four major apoB-containing lipoprotein classes (Table  4 ) demonstrated that the drug had profoundly altered these species. A decrease in relative cholesteryl ester content was the most noticeable change in all fractions; in IDL, in particular, cholesteryl ester fell from 39.3% to 35.3%, whereas the triglyceride content rose from 11.5% to 18.6%. Simvastatin also decreased the percentage of free cholesterol in IDL and LDL.
The influence of simvastatin therapy on apoB metabolism was examined by studying the subjects before and during drug treatment (Figures 3, 4 , and 5). Figures  5A-5D show the full pattern of decay curves for all lipoprotein species before and during therapy for patient J.R. ApoB disappeared rapidly from the VLDL] flotation interval and appeared virtually quantitatively in VLDL 2 over a period of 12-24 hours after injection. The decay of radioactive apoB in VLDL 2 was slower than in VLDLi, taking up to 5 days to reduce to 1% of the injected dose. Drug therapy did not appear to affect the clearance rate of either VLDL! apoB ( Figures 3A,  3B , 4A, and 4B) or VLDL 2 apoB ( Figures 3C, 3D, 4C , and 4D). Similarly, the extent of transfer of radioactive apoB into IDL was comparable before and during simvastatin therapy for both tracers. However, the decay rate of IDL apoB was faster while on the drug, and the peak value attained in the LDL fraction was consistently less than at baseline. In Figure 5C LDL apoB radioactivity reaches a maximum of 25% of injected dose about 24 hours after VLDL 2 injection, whereas in Figure 5D the LDL apoB maximum is only 13%. This finding indicates that the metabolic fate of IDL apoB is markedly affected by therapy, with more material being lost directly from the circulation rather than being converted to LDL. In the subject illustrated in Figure 5 (J.R.), the clearance rate of LDL apoB radioactivity was also increased during simvastatin therapy. Kinetic rate constants and apoB fluxes were derived by compartmental modeling. The results are summarized in Table 5 ; individual kinetic constants and masses are given in the appendixes.
VLDL, apoB synthesis, pool size, and fractional transfer rate to VLDL 2 were unchanged by therapy, and although the mean direct fractional catabolic rate of VLDL, apoB increased by some 209%, from 1.7 to 5.3 pools/day, this just failed to reach statistical significance (p=0.06). The VLDL 2 apoB pool size remained unchanged on drug as did the amount of material derived from VLDL! or by direct input. There was, however, a rise in the mean VLDL 2 apoB direct fractional catabolic rate of 79%, from 1.69 to 3.02 pools/day. IDL formation from VLDL 2 , presumably by delipidation, was the same before and during simvastatin therapy. The IDL apoB plasma pool size fell significantly from 1,043 to 762 mg (27%, p<0.01) due entirely to an increase in direct catabolism (147%, p<0.05) of this fraction. In contrast, the IDL-to-LDL fractional transfer rate was not affected by the drug. Direct synthesis of LDL apoB decreased in four of the seven subjects, and the LDL apoB synthetic rate from VLDL 2 and IDL showed a similar pattern, with five of the seven subjects showing a fall. The observed LDL apoB plasma pool showed a highly significant fall in response to simvastatin therapy of 42% (from 2,926 to 1,687 mg; /?<0.005) due to a combination of reduced synthetic and increased catabolic rates. The mean fractional catabolic rate of LDL apoB, which we expected to increase in response to therapy, did indeed rise by 33%, but because of the scatter of responses this did not achieve overall significance. In this limited group of subjects it was the reduction in LDL apoB synthesis rather than any change in catabolism that was the predominant factor in reducing LDL. Before therapy, 30% of apoB entering the delipidation cascade in these hyperlipidemic subjects was converted to LDL. After therapy the input •Differences between means were assessed by the paired Student's / test. tDirect synthesis in LDL was calculated as the difference between the total absolute catabolic rate (observed massxoverall fractional catabolic rate) and the input from VLDL and IDL.
§The observed plasma LDL apoB pool is calculated from the plasma volume (ml) x LDL apoB concentration (mg/ml).
VThe calculated plasma LDL apoB pool is computed by the SAAM 30 program, is derived from labeled VLDL and IDL precursors, and does not include any direct unlabeled input. remained the same, but direct catabolism from VLDL 2 and IDL density ranges was increased significantly (p<0.05), so that only 16% was processed to LDL ( Figure 6 ). It was also of note that the mean calculated total apoB synthetic rate increased from 2,440 to 3,508 mg/day (p=0.06) in response to therapy (Table 5) .
From these data it is clear that simvastatin is responsible for greater effects on lipoprotein metabolism than a simple increase in LDL catabolism. In an attempt to correlate the changes in LDL kinetics with changes in LDL substructure, we examined the relation between the LDL apoB synthetic parameters and the plasma concentrations of LDL-I, -II, and -III. LDL-I and -II were grouped together for this analysis, since they appeared to behave in a similar fashion that was distinct from that of LDL-III. The relations between LDL-I+ 11 and LDL direct input and LDL-III and LDL direct input are shown in Figures 7 and 8 . The strong correlation between LDL-I+II and LDL direct input before (r=0.89, /?<0.01) and after (r=0.87, /?<0.02) therapy and the lack of correlation between LDL-III and LDL direct input was unexpected. We also examined the relation between LDL-III and LDL synthesis from VLDL 2 
Discussion
The mechanism by which the HMG CoA reductase inhibitors (statins) achieve their principal effect of lowering LDL cholesterol has been a particular focus of research over the last 10 years. In an early study Bilheimer et al 13 examined LDL turnover in FH subjects treated with mevinolin (lovastatin). They attributed the drug's LDL lowering to an increase in the apoLDL fractional catabolic rate, which was thought to be secondary to the effect of the drug in suppressing cholesterol synthesis, reducing intracellular cholesterol concentrations and consequently promoting the activity of the LDL (apoB/E) receptor. A close parallel was drawn between the mechanism of action of the statins and that reported previously 13 for bile acid sequestrant resins, which also showed an increase in receptor-mediated LDL catabolism. No overall change in the apoLDL synthesis rate was seen in these statin-treated FH subjects, although it was noted that five of the six examined showed reductions of up to 22% in this parameter. Further studies in patients with polygenic hypercholesterolemia (not attributable to FH) emphasized this dual action. Grundy and Vega"- 31 reported that both decreased input and increased clearance had to be invoked to explain the reduction in LDL in such patients. These workers investigated apoB metabolism in VLDL, IDL, and LDL and found that pravastatin therapy altered VLDL production but not the catabolism of any of these lipoprotein classes. 12 A summary of the findings to date of studies with this group of drugs is that: 1) functional LDL receptors are essential for their 
FlGURE 8. Scatterplot showing correlation between low density lipoprotein (LDL)-III and LDL direct input at baseline (m) and during simvastatin therapy (a).
action, with FH homozygotes showing no response to the drug in terms of altered plasma LDL levels or turnover 32 ; 2) subjects with a pronounced catabolic defect, i.e., FH heterozygotes, show an increase in LDL fractional catabolic rate on statins; and 3) other hypercholesterolemic patients are as likely to demonstrate reduced apoB input into LDL as increased clearance of the lipoprotein, although all subjects show a consistent 35-40% reduction in LDL pools, however this is achieved. The heterogeneous changes in the moderately hypercholesterolemic group of subjects perhaps indicate an as-yet-unappreciated, underlying variability in apoB metabolism in the population. This group of subjects will, of course, be the largest group to receive these drugs.
Previously we demonstrated the usefulness of dualtracer (VLDL] and VLDL 2 ) studies in delineating the role of receptors and Upases in the regulation of the VLDL-to-LDL delipidation cascade. Investigations in receptor-defective FH homozygotes 14 and normolipidemic subjects who have defective apoE ligands 15 revealed multiple steps in which apoB/E receptors are involved in this metabolic pathway. If activation of receptors is the single most important action of the statins, then this should be evident throughout the cascade; the results reported here indicate that this is the case. Simvastatin clearly stimulated lipoprotein catabolism at various stages in the VLDL-to-LDL conversion, and a number of these kinetic changes were linked to perturbations in the structure and composition of apoB-containing lipoproteins. The drug's influence was not restricted to VLDL and LDL in our study. HDL 2 , the minor HDL subfraction that is believed to have cardioprotective properties, was increased by 62%. This change was apparently linked to the fall in total plasma triglyceride levels but could not be related to a perturbation in the kinetic behavior of any particular VLDL subfraction.
The major finding of the present study was that simvastatin stimulated direct catabolism of lipoproteins throughout the VLDL delipidation cascade, presumably as a result of its ability to increase apoB/E receptor activity ( Figure 6 and Table 5 ). Certainly the pathways activated by the drug are those identified from previous turnover studies as probably involving receptor-mediated catabolism.
14 Lipolysis as measured by the fractional transfer rate of VLDL) to VLDL 2 and then on to IDL and LDL was not affected by therapy (Table 5) .
Since it is believed that apoB/E receptors play a major role in lipoprotein metabolism toward the denser end of the S f 0-400 spectrum, it is not surprising that IDL and LDL were the fractions most affected by therapy. There was not only a reduction in the plasma concentration but also a change in their composition. On therapy, as reflected in the compositional data (Table 4) , there was a tendency for the cholesteryl ester content of all the apoB-containing fractions to fall. This was most clearly seen in IDL, where absolute cholesteryl ester content decreased approximately 40%, while that of triglycerides was unaltered. These changes could have been caused by either the synthesis of lipoproteins of altered composition, perturbations of cholesteryl ester transfer protein (CETP) activity, or the selective removal of cholesteryl ester-rich subpopulations from these lipoproteins. Bagdade et al 33 reported that statins do not appear to affect CETP, and based on the kinetic changes noted in the present study, we favor the last hypothesis, that increased receptor activity causes the selective removal of cholesteryl ester-rich remnant lipoproteins in VLDL and IDL. There is in vitro evidence from cell-culture studies that cholesteryl esterrich remnant lipoproteins have a higher affinity for receptors than their triglyceride-rich counterparts. 34 Multicompartmental modeling showed that within the IDL subsystem, it was the remnant pool (compartment 9, Appendix 4) that appeared to be most influenced by simvastatin therapy. This interpretation is also in accord with the findings that statins, uniquely among lipidlowering drugs, decrease the VLDL remnant population in type III hyperlipoproteinemia. 9 They alone are able to decrease the cholesteryl ester-to-triglyceride ratio within this lipoprotein fraction toward normality. It is noteworthy that IDL appeared to be the most affected of all the apoB-containing lipoproteins, both in terms of its altered composition and its metabolic fate. This is significant with regard to the drug's mechanism of action, since IDL possibly has the highest affinity of all the lipoprotein fractions to bind to the LDL receptor because it contains both apoB and the ancillary ligand apoE. This statin-induced effect on IDL may also be clinically important because this species is considered to be particularly atherogenic. 35 These findings are at variance with the study of Vega et al, 12 who found that the catabolism of VLDL, IDL, and LDL was not affected by statin (pravastatin therapy). Rather, VLDL apoB synthesis was diminished in their patients during drug treatment. The reasons for the discrepancy between the two reports are not clear. It is doubtful that simvastatin and pravastatin have separate actions and likely that the interindividual variation in response to the drugs seen in both studies led us to different conclusions as to the overall effect of the drugs. The patients in the study of Vega et al, like ours, showed no significant reduction in plasma triglyceride levels, but they did show a diminution in VLDL-C. In our study VLDL-C levels were not significantly affected by drug therapy. In view of the known metabolic effects of the statins, we favor the idea that in most subjects the main action is to promote the removal of apoB/Econtaining lipoproteins from the delipidation cascade by direct catabolism.
As noted above, increased catabolism alone did not explain the dramatic statin-induced fall in LDL levels in moderately hypercholesterolemic subjects. Decreased apoB transport down the delipidation cascade leading to diminished LDL production was equally important (Figure 6 ). In this study we took the opportunity to examine the relation between apoB kinetics and LDL subfraction distribution as defined by a recently developed density gradient technique. 18 As in most subjects, our patients demonstrated the presence of three LDL subtractions differing in size and density both before and during simvastatin therapy. In some subjects LDL-II was the predominant species, whereas in others small, dense LDL-III was the major form found. Overall, the drug lowered LDL-I and LDL-II concentrations, whereas small, dense LDL-III were not significantly affected. These changes are concordant with the idea that larger lipid-rich LDLs are more easily removed by apoB/E receptors 36 by increases in receptor activity. To our surprise, however, we observed a strong positive correlation between the concentration of LDL-I and LDL-II combined and what we computed as direct LDL synthesis both before and during simvastatin therapy. This kinetic parameter, which is calculated as the mass of LDL unaccounted for by VLDL-to-LDL catabolism, is the topic of considerable controversy. 37 The argument centers on whether the liver can elaborate LDL per se or, as has been argued by Marzetta et al, 38 actually produces a rapidly metabolized LDL precursor. Whatever the route of apoB input into the LDL density range, the pathway appears to be substantial in many patients and accounts for the variation in LDL-I and LDL-II levels in our hypercholesterolemic patients. It is not apparently affected by statin therapy as noted here (Table 5 ) and by Vega et al, 12 although this conclusion must be considered tentative since the kinetic parameters for LDL derived by direct synthesis are extrapolated from the behavior of LDL that is derived from VLDL.
Our interpretation of the correlations between LDL kinetics and subtraction distribution and the effects of statins is that in these moderately hypercholesterolemic subjects, LDL comes from two sources. One source is the classical VLDL-to-LDL delipidation cascade, and it is this that is specifically affected by statin therapy. Statins indeed seem to have a uniform effect on this pathway, as most individuals show an approximately 50% reduction in the LDL derived from this route. The other pathway, that of direct LDL input, is highly variable in our subjects and is responsible for the variation in their levels of LDL-I and LDL-II. Clearly, more work must be done to delineate the properties of this pathway and to examine why it remains resistant to statin therapy. Effects of statins on the LDL subtraction profile must be compared with the effects of other lipid-lowering agents such as fibrates and nicotinic acid. We found that triglyceride-lowering drugs alter the distribution of LDL subtractions toward the less dense LDL-I and LDL-II with a reduction in LDL-III. 19 Statin therapy, on the other hand, appeared to reduce LDL-I and LDL-II primarily, as has been found for cholestyramine therapy. 19 This differential effect of these drugs on LDL subtractions will have consequences for their potential antiatherogenic properties. Further studies will elucidate how LDL subtraction patterns are controlled and affected by drug therapy. We conclude that statin therapy in moderate hypercholesterolemia is associated with changes throughout the apoB-containing lipoproteins and also in HDL. The changes are consistent with the known mechanisms of action of the drug and result in alterations in both the composition and structure of lipoproteins. 32 ; 2) subjects with a pronounced catabolic defect, i.e., FH heterozygotes, show an increase in LDL fractional catabolic rate on statins; and 3) other hypercholesterolemic patients are as likely to demonstrate reduced apoB input into LDL as increased clearance of the lipoprotein, although all subjects show a consistent 35-40% reduction in LDL pools, however this is achieved. The heterogeneous changes in the moderately hypercholesterolemic group of subjects perhaps indicate an as-yet-unappreciated, underlying variability in apoB metabolism in the population. This group of subjects will, of. course, be the largest group to receive these drugs.
Previously we demonstrated the usefulness of dualtracer (VLDL, and VLDL 2 ) studies in delineating the role of receptors and Upases in the regulation of the VLDL-to-LDL delipidation cascade. Investigations in receptor-defective FH homozygotes 14 and normolipidemic subjects who have defective apoE ligands 15 revealed multiple steps in which apoB/E receptors are involved in this metabolic pathway. If activation of receptors is the single most important action of the statins, then this should be evident throughout the cascade; the results reported here indicate that this is the case. Simvastatin clearly stimulated lipoprotein catabolism at various stages in the VLDL-to-LDL conversion, and a number of these kinetic changes were linked to perturbations in the structure and composition of apoB-containing lipoproteins. The drug's influence was not restricted to VLDL and LDL in our study. HDL 2 , the minor HDL subfraction that is believed to have cardioprotective properties, was increased by 62%. This change was apparently linked to the fall in total plasma triglyceride levels but could not be related to a perturbation in the kinetic behavior of any particular VLDL subfraction.
14 Lipolysis as measured by the fractional transfer rate of VLDL, to VLDL 2 and then on to IDL and LDL was not affected by therapy (Table 5) .
Since it is believed that apoB/E receptors play a major role in lipoprotein metabolism toward the denser end of the S r 0-400 spectrum, it is not surprising that IDL and LDL were the fractions most affected by therapy. There was not only a reduction in the plasma concentration but also a change in their composition. On therapy, as reflected in the compositional data (Table 4) , there was a tendency for the cholesteryl ester content of all the apoB-containing fractions to fall. This was most clearly seen in IDL, where absolute cholesteryl ester content decreased approximately 40%, while that of triglycerides was unaltered. These changes could have been caused by either the synthesis of lipoproteins of altered composition, perturbations of cholesteryl ester transfer protein (CETP) activity, or the selective removal of cholesteryl ester-rich subpopulations from these lipoproteins. Bagdade et al 33 reported that statins do not appear to affect CETP, and based on the kinetic changes noted in the present study, we favor the last hypothesis, that increased receptor activity causes the selective removal of cholesteryl ester-rich remnant lipoproteins in VLDL and IDL. There is in vitro evidence from cell-culture studies that cholesteryl esterrich remnant lipoproteins have a higher affinity for receptors than their triglyceride-rich counterparts. 34 Multicompartmental modeling showed that within the IDL subsystem, it was the remnant pool (compartment 9, Appendix 4) that appeared to be most influenced by simvastatin therapy. This interpretation is also in accord with the findings that statins, uniquely among lipidlowering drugs, decrease the VLDL remnant population in type III hyperlipoproteinemia. 9 They alone are able to decrease the cholesteryl ester-to-triglyceride ratio within this lipoprotein fraction toward normality. It is noteworthy that IDL appeared to be the most affected of all the apoB-containing lipoproteins, both in terms of its altered composition and its metabolic fate. This is significant with regard to the drug's mechanism of action, since IDL possibly has the highest affinity of all the lipoprotein fractions to bind to the LDL receptor because it contains both apoB and the ancillary ligand apoE. This statin-induced effect on IDL may also be clinically important because this species is considered to be particularly atherogenic. 35 These findings are at variance with the study of Vega et al, 12 who found that the catabolism of VLDL, IDL, and LDL was not affected by statin (pravastatin therapy). Rather, VLDL apoB synthesis was diminished in their patients during drug treatment. The reasons for the discrepancy between the two reports are not clear. It is doubtful that simvastatin and pravastatin have separate actions and likely that the interindividual variation in response to the drugs seen in both studies led us to different conclusions as to the overall effect of the drugs. The patients in the study of Vega et al, like ours, showed no significant reduction in plasma triglyceride levels, but they did show a diminution in VLDL-C. In our study VLDL-C levels were not significantly affected by drug therapy. In view of the known metabolic effects of the statins, we favor the idea that in most subjects the main action is to promote the removal of apoB/Econtaining lipoproteins from the delipidation cascade by direct catabolism.
As noted above, increased catabolism alone did not explain the dramatic statin-induced fall in LDL levels in moderately hypercholesterolemic subjects. Decreased apoB transport down the delipidation cascade leading to diminished LDL production was equally important (Figure 6 ). In this study we took the opportunity to examine the relation between apoB kinetics and LDL subfraction distribution as defined by a recently developed density gradient technique. 18 As in most subjects, our patients demonstrated the presence of three LDL subfractions differing in size and density both before and during simvastatin therapy. In some subjects LDL-II was the predominant species, whereas in others small, dense LDL-III was the major form found. Overall, the drug lowered LDL-I and LDL-II concentrations, whereas small, dense LDL-III were not significantly affected. These changes are concordant with the idea that larger lipid-rich LDLs are more easily removed by apoB/E receptors 36 37 The argument centers on whether the liver can elaborate LDL per se or, as has been argued by Marzetta et al, 38 actually produces a rapidly metabolized LDL precursor. Whatever the route of apoB input into the LDL density range, the pathway appears to be substantial in many patients and accounts for the variation in LDL-I and LDL-II levels in our hypercholesterolemic patients. It is not apparently affected by statin therapy as noted here (Table 5 ) and by Vega et al, 12 although this conclusion must be considered tentative since the kinetic parameters for LDL derived by direct synthesis are extrapolated from the behavior of LDL that is derived from VLDL.
Our interpretation of the correlations between LDL kinetics and subfraction distribution and the effects of statins is that in these moderately hypercholesterolemic subjects, LDL comes from two sources. One source is the classical VLDL-to-LDL delipidation cascade, and it is this that is specifically affected by statin therapy. Statins indeed seem to have a uniform effect on this pathway, as most individuals show an approximately 50% reduction in the LDL derived from this route. The other pathway, that of direct LDL input, is highly variable in our subjects and is responsible for the variation in their levels of LDL-I and LDL-II. Clearly, more work must be done to delineate the properties of this pathway and to examine why it remains resistant to statin therapy. Effects of statins on the LDL subfraction profile must be compared with the effects of other lipid-lowering agents such as fibrates and nicotinic acid. We found that triglyceride-lowering drugs alter the distribution of LDL subfractions toward the less dense LDL-I and LDL-II with a reduction in LDL-III. 19 Statin therapy, on the other hand, appeared to reduce LDL-I and LDL-II primarily, as has been found for cholestyramine therapy. 19 This differential effect of these drugs on LDL subfractions will have consequences for their potential antiatherogenic properties. Further studies will elucidate how LDL subfraction patterns are controlled and affected by drug therapy. We conclude that statin therapy in moderate hypercholesterolemia is associated with changes throughout the apoB-containing lipoproteins and also in HDL. The changes are consistent with the known mechanisms of action of the drug and result in alterations in both the composition and structure of lipoproteins. 
